Dateline City:
WHITEHOUSE STATION, N.J. & NEW YORK
WHITEHOUSE STATION, N.J. & NEW YORK--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States
and Canada (Merck), and Pfizer Inc. (NYSE:PFE) today announced that
they have entered into a worldwide (except Japan) collaboration
agreement for the development and commercialization of Pfizers
ertugliflozin (PF-04971729), an investigational oral sodium glucose
cotransporter (SGLT2) inhibitor being evaluated for the treatment of
type 2 diabetes.
Language:
English
Contact HTML:
Merck Media Relations:Steven Cragle: (908) 423-3461Kim Hamilton: (908) 423-6831orPfizer Media Relations:Joan Campion: (212) 733-2798orMerck Investor Relations:Carol Ferguson: (908) 423-4465Justin Holko: (908) 423-5088orPfizer Investor Relations:Chuck Triano: (212) 733-3901
Ticker Slug:
Ticker: MRK Exchange: NYSE
Ticker: PFE Exchange: NYSE
read more